Similarly, in HER2+ breast cancer, IGF-1R cooperates with HER2/ERBB2 signaling to sustain downstream PI3K/AKT and MAPK activation, thereby undermining the efficacy of HER2-targeted agents such as trastuzumab [60]. The gene discussed is PIK3CA; the disease is breast carcinoma.